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TIE &II of this study was to test the hypothesis that either 
the cycboxygenase inhibitor aspirin or the tbrombozane A2 
receptur antago& sulotroban exerts a direct myocprdial 
effect that enhances myocardial salvage aiforded by reper- 
ffision. Acconlingly, 21 mcdbetized dogs underwent suture 
occlusion of the coronary artery. 
At 2.5 b aiter ived intravenous 
streptokii (2 y we@ over 30 min) and 
were randomized to the foilowing groups: group I (n = 7) 
received no additional treabnent, group II (n = 7) received 
aspirin (5 mg/kg iatravenously) and group III (n = 7) 
received sulotroban (10 n&g followed by 10 mgkg per b 
intravenously). At 3 h after occlusion, the dogs underwent 
coronary reperfusion for the next 3 h. 
the extent of myocardiil hemorrhage were si 
tbree study groups. Infarct size 
perfused zone was significantly 
hemorrhage irrespective of trea 35 f 9% versus 
63 * 5%, p < 0.01). 
enhanced myocardial salv 
dial effect as compared 
potential benefits of comb 
therapy are likely to be Ihm 
Myocardial infarct size as a percent of the hypoperfbsed 
zone was similar among dogs in group I (42 f SS), group 
II (41 f 10%) and group III (45 f 11%). The incidenceand 
salvage tiorded by coronary reperfimion. 
(,? Am CoU Cardio~ 1990;15:2662-6) 
Recent interest in thrombolytic therapy for acute myocardial 
infarction raised the possibility that myocardial salvage after 
coronary artery reperfusion could be enhanced by adjunc- 
tive pharmacologic therapy. This concept was supported by 
the findings of the International Study of Infarct Survival 
(ISIS-2) Trial (I), which showed a reduction in early mo, &al- 
ity rates in patients with suspected myocardial infarction 
treated with a combination of streptokinase and aspirin. 
These results could be related to 1) an increased reperfusion 
efficacy, 2) a reduced reocclusion rate, 3) an effect on the 
microvasculature in the reperfused zone, or 4) a direct 
myocardial effect of combined therapy. 
boxane A2 is a potent vasoconstrictor, platelet aggregator 
and membfine lytic agent ($6). Accordingly, agents that 
a!Yect platelet aggregation or thromboxane At metabolism, 
or both, have been extensiveb studied in various models of 
myocardial ischemia (7-14). H,?wever, little attention has 
been given to their additive effec:s on myocardiai salvage in 
the presence of successful thrombolytic therapy. 
Platelets are a major component of occlusive coronary 
thrombus (2,3). In addition, they accumulate in the infarcting 
myocardium (4, and the platelet-derived mediator throm- 
The goal of this study was to evaluate a direct myocardial 
effect of the cyclooxygenase inhibitor aspirin and the throm- 
boxane A2 receptor antagoilist sulotroban (15,16) on myo- 
cardial infarct size in the presence of coronary artery reper- 
fusion. Specifically, the effect of these interventions on 
infarct size and myocardial hemorrhage in combination with 
the thrombolytic agent streptokinase was studied indepen- 
dent of their effect on clot lysis at the site of coronary 
occlusion. 
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Experimental preparation. Twenty-five dogs were anes- 
thetized with sodium pentobarbital (30 mgkg body weight 
intravenously), intubated endotracheally and ventilated with 
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st-Roussel) and were ran- 
d to the fol~ow~og group I (n = IO), control 
dogs that received no additional treatment. 
Six hours after occlusion (that is, 3 h after reperfusion), the 
dogs were killed with an intravenous injection of potassium 
chloride, and the heart was excised. The left ventricle was 
then removed, frozen at -70°C and cut into 3 mm thick 
the apex to the site of occlusion. 
alysis. Infarct size and hypoperfused zone were 
by planimetry after incubation of the left ventric- 
ular slices with t~phe~y~tet~azo~ium chloride and after auto- 
radiography, respectively, according to the technique de- 
scribed previously (17-19). In each dog, the following 
variables were calculated: 1) percent of cross-sectional areas 
of the slices of the left ventricle that showed myocardial 
necrosis; 2) percent of cross-sectional areas of the slices of 
the left ventricle that was initially (1 min after 
hypoperfused as determined by autoradiogra~ 
spot”); 3) percent of hypoperfused zone that 
infarction (this method expressed infarct size as a percent of 
the hypoperfused zone in each dog and was used to examine 
whether the intervention was effective in salvaging myocar- 
dial cells); and 4) extent of gross myocardial 
determined by planimetry and graded in a semiquantitative 
fashion as follows: grade 0 = no gross hemorrhage, grade 1 + 
uhs were expressed as mean val- 
er exact test was use 
117 -c 5 and 112 f 5 
myocardial hemorrhage in the aspirin and sulotroban groups 
compared with the control group. The ratio of infarct size to 
hypoperfused zone was 63 + 5% in dogs with myocardial 
hemorrhage (n = 6) versus 35 -I- 9% (p < 0.01) in those 
without hemort,hage (n = 15) despite a corn~~a~~e hypo- 
pe one in both groups (Fig. 2). 
ies, There were no signi rences in 
systolic, diastolic and mean arterial p 
control, aspirin and su~otroba~ groups 
coronary artery occlusion and after repe 
rate in the aspirin group was faster (p < 0 
occlusion compared with that in the control gr 
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goal was to enhance clot lysis or prevent sudden coronary 
reocclusion, or both. The role of aspirin in myocardial 
infarction independent of its effect on coronary tbro~bMs is 
more controversial. Aspirin has been found to reduce the 
extent of myocardiai necrosis induced by epine~b~~e infu- 
sion, which is associated with increased platelet aggregation 
(23). Furthermore, aspirin reduced the incidence of ventric- 
ular fibrillation in dogs after coronary artery occlusion 
(4,24). Although aspirin increased collateral fro 
border of ischemic regions in some studies (25,26) 
on infarct size has not been Mniform~y 
tree and Lefer (27) found no changes in 
release or ST segment elevation after 
artery occlusion in cats pretreated with aspirin. 
(26) demonstrated that aspirin failed to 
dogs despite inhibition of platelet aggregation and a signifi- 
cant increase in collateral flow. It could he postulated that 
the lack of effect of aspirin on infarct size was related to the 
inhibitory effect of aspirin on endothelial cell cyclooxygen- 
ase and a decrease in prostacyclin producti 
Thromboxane A2 receptor antagonists. 
thromboxane A2 synthetase inhibitors and 
receptor antagonists have been developed. Theoretically, 
the latter group of agents may be more advantageous than 
cyclooxygenase inhibitors in treating myocardial ischemia 
because thromboxane Az receptor antagonists do not de- 
crease prostacyclin production. Furthermore, they do not 
result in accumulation of endoperoxide intermediates, which 
may have a deleterious effect on the ischemic myocardium 
(28). Different thromboxane A, receptor antagonists have 
been shown to reduce infarct size after permanent coronary 
artery occlusion (29-31); in those studies, sulotroban was 
found to reduce the decrease in myocardial creatine kinase 
activity in the ischemic myocardium if the intervention was 
started early (15 to 30 mitt) after coronary occlusion and no 
reperfusion was carried out. In addition, Osborne and Lefer 
(32) suggested that long-term therapy with a thromboxane Az 
receptor antagonist may have an antiatherogenic effect in 
atherosclerotic rabbits. Our study showed that in a 3 h 
occlusion-reperfusion model, neither a cyclooxygenase ir:. 
hibitor nor a specific thromboxane A, receptor antagonist 
afforded additional myocardial salvage compared with reper- 
fusion alone. These results differ from studies by others 
(33,34) who reported a further reduction in infarct size after 
thromboxane A, receptor antagonist administration in the 
sts on my~~dia~ sal- 
There are several 
reasons that may account for these observed differences. 
First, the duration of ischemia was 3 h in our study as 
opposed to only 90 min in the studies by Grover et al. (33) 
and Bhat et al. (34). It is conceivable that the thromboxane 
Az receptor antagonist and reperfusion therapy have an 
additive effect on myocardial salvage only in the very early 
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Figure 1. Left panel, Extent of the hypoperfused zone (HZ) ex- 
pressed as a percent of the left ventricle (%LV). The extent of the 
hypopetfused zone was similar in the three study groups. Right 
panel, Infarct size (IS) expressed as a percent of the hypoperfused 
zone (HZ). Values were similar in the three study groups. C = group 
I control dogs that received streptokinase intravenously; ASA = 
group II dogs that received streptokinase and aspirin intravenously: 
SUL = group III dogs that received streptokinase and sulotroban 
intravenously. 
iscussi 
Our findings indicate that neither the cyclooxygenase 
inhibitor aspirin nor the thromboxane A2 receptor antagonist 
sulotroban directly enhances myocardial salvage in an oc- 
perfusion model. 
of antiplatelet agents on mystic ischemis. As- 
pirin. The cyclooxygenase inhibitor aspirin and the throm- 
boxane A, receptor antagonists have been shown to abolish 
spontaneous cyclic reductions in coronary flow that are 
associated with platelet aggregation at the site of cn’tical 
coronary artery stenosis (20-22). This concept provided the 
rationale for the widespread use of aspirin in patients under- 
going thrombolytic therapy for myocardial infarction. The 
Figure 2. Left panel, Comparable size of the hypoperfused zone 
(HZ) expressed as a percent of the left ventricle (LV%) in dogs with 
(28 f 2%) and without (29 -F 3%) gross myocardial hemorrhage. 
el, Significantly larger infarct sizelhypoperfused zone 
(IS/HZ) ratio was found in the presence of myocardial hemorrhage, 
indicating less myocardial salvage. 
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Before Coronary 
b)CCllPSiCMl 
After @oroa,ary Occlusion 
I.5 min 2 h 30 min 
During infusion keperfusion 
2 h 45 mio 4h 6h 
SK 10828 IIS? 98 -c 5 125 _c 10 93 -c 3 
(group 1. n = 7) 
SK + ASA 105 2 4 102 r 7 PO? + 7 97r9 110”7 11725 88&7 103 ?r 7 134 5 24 86 -c 4 128 + 7 80 t 4 
(group If, n = 7) 
SK t SUL 94+14 107t5 1175II f 4 103 2 9 112 t 5 98 + 13 109 -c 7 117 + 9 90 + 9 130 f 10 86 c 9 
(group 111. n = 7) 
p value NS NS NS NS NS NS NS NS * NS NS NS 
s are mean va = mean arterial pressure; ASA = aspirin; HR = heart rate; 
SK = streptokinase; SUL = sulotroban. 
lotroban started at 2. 
in our study, strepto 
fusion to simulate t 
t results 
coronary occlusion a 
with a~ti~latelet and throm- 
only streptokinase) and groups treated with combined ther- 
apy. Interestingly, myocardial salvage was timited in dogs 
with gross myocardial hemo~hage irrespective of treatment. 
In addition, the lack of enhanced myocardial salvage in 
groups treated with the cyclo~xyge~ase inhibitor and the 
thromboxane A2 receptor antagonist in our study could not 
be explained on the basis of differences in myocardial 
oxygen consumption between the treated and control 
groups. 
Thus, QW study did not emonstrate enhanced 
dial salvage with anti~lateIet therapy after 3 h of coronary 
occlusion and reperfusion, an interval that is more relevant 
to the clinical setting as opposed to shorter periods of 
iscltemia studied previously (33,34). In addition, although 
myocardial hemorrhage limited myocardial salvage, the 
combination of thrombolytic and antiplatelet agents did not 
increase the incidence of myocardial hemorrhage. 
artery patency. There is a 
affecting tbromboxane A, sy 
enase inhibitor aspirin nor 
thromboxane A2 receptor antagonist sulotroban e 
myocardial salvage by mzans of a direct myocardial effect. 2) 
Any potential benefits of combined thrombolytic and anti- 
platelet therapy are likely to be limited to their vascular 
effects (for example, increased reperfusion efficacy or re- 
duced reocclusion rate, or both). 3) Myocardial hemorrhage 
may limit myocardial salvage afforded by coronary reperfu- 
sion. 
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